Suprachoroidal gene transfer with nonviral nanoparticles in large animal eyes.
Jikui ShenRaquel Lima E SilvaMingliang ZhangKathryn M LulySean F HackettStephany Y TzengShirley M LowmasterSydney R ShannonDavid R WilsonJordan J GreenPeter A CampochiaroPublished in: Science advances (2024)
Suprachoroidal nonviral gene therapy with biodegradable poly(β-amino ester) nanoparticles (NPs) provides widespread expression in photoreceptors and retinal pigmented epithelial (RPE) cells and therapeutic benefits in rodents. Here, we show in a human-sized minipig eye that suprachoroidal injection of 50 μl of NPs containing 19.2 μg of GFP expression plasmid caused GFP expression in photoreceptors and RPE throughout the entire eye with no toxicity. Two weeks after injection of 50, 100, or 200 μl, there was considerable within-eye and between-eye variability in expression that was reduced 3 months after injection of 200 μl and markedly reduced after three suprachoroidal injections at different locations around the eye. Reduction of bacterial CpG sequences in the expression plasmid resulted in a trend toward higher expression. These data indicate that nonviral suprachoroidal gene therapy with optimized polymer, expression plasmid, and injection approach has potential for treating photoreceptors throughout the entire retina of a human-sized eye.
Keyphrases
- poor prognosis
- gene therapy
- escherichia coli
- endothelial cells
- binding protein
- ultrasound guided
- long non coding rna
- optical coherence tomography
- gene expression
- oxidative stress
- diabetic retinopathy
- induced apoptosis
- cell proliferation
- crispr cas
- machine learning
- cell death
- endoplasmic reticulum stress
- climate change
- artificial intelligence
- induced pluripotent stem cells
- data analysis